Genitourinary Cancers

The world of precision medicine is upon us and we as providers, especially those involved in the management of oncology patients, will need to be conversant and have an understanding of these various pathways and drivers in order to more effectively manage our patients

There are many processes for a urology practice to consider when partnering with a specialty pharmacy, including time and capital investments.

The combination of lenvatinib and everolimus more than doubled progression-free survival and extended overall survival by 10.1 months compared with everolimus alone as a second-line treatment for patients with metastatic renal cell carcinoma.

Interest is high among urologists and medical oncologists with "the explosion of checkpoint blockade inhibition studies" that initially made inroads in melanoma and non-small cell lung cancer, but is also gaining traction in bladder cancer.

Two urine biomarkers, aquaporin 1 and perilipin 2, could be the key to the development of a simple urine test that leads to the detection of asymptomatic, early-stage kidney cancer.

Daniel Petrylak, MD, Professor of Medicine and of Urology; Professor, Signal Transduction Research Program at Yale Cancer Center discusses the future of immunotherapy in bladder cancer.

A fourth of patients with advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor pembrolizumab.

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses the association between urinary tract infections (UTI) and worse bladder cancer outcomes in the Medicare population.

Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.

Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.

Laurence Albiges, MD, visiting scientist, Dana-Farber Cancer Institute, discusses how oncologists can treat patients with metastatic renal cell carcinoma (mRCC) based off of findings from a study that looked at the impact of body mass index (BMI) on outcomes of these patients.

Management of elevated PSAs, or the next testing equivalent, and prostate cancer should default to the urology world, just like always.

Arjun V. Balar, MD, oncologist, NYU Langone Medical Center, discusses the results of the phase III ASSURE trial, which compared sorafenib and sunitinib in patients with locally advanced renal cell carcinoma (RCC).